274 related articles for article (PubMed ID: 18401435)
1. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.
Errington F; White CL; Twigger KR; Rose A; Scott K; Steele L; Ilett LJ; Prestwich R; Pandha HS; Coffey M; Selby P; Vile R; Harrington KJ; Melcher AA
Gene Ther; 2008 Sep; 15(18):1257-70. PubMed ID: 18401435
[TBL] [Abstract][Full Text] [Related]
2. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.
Ilett EJ; Bárcena M; Errington-Mais F; Griffin S; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Limpens RW; Mommaas M; Hoeben RC; Vile RG; Melcher AA
Clin Cancer Res; 2011 May; 17(9):2767-76. PubMed ID: 21389099
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.
Ilett EJ; Prestwich RJ; Kottke T; Errington F; Thompson JM; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Vile RG; Melcher AA
Gene Ther; 2009 May; 16(5):689-99. PubMed ID: 19282847
[TBL] [Abstract][Full Text] [Related]
4. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection.
Norman KL; Hirasawa K; Yang AD; Shields MA; Lee PW
Proc Natl Acad Sci U S A; 2004 Jul; 101(30):11099-104. PubMed ID: 15263068
[TBL] [Abstract][Full Text] [Related]
5. Noncanonical Cell Death Induction by Reassortant Reovirus.
Rodríguez Stewart RM; Raghuram V; Berry JTL; Joshi GN; Mainou BA
J Virol; 2020 Oct; 94(22):. PubMed ID: 32847857
[TBL] [Abstract][Full Text] [Related]
6. Exploring host factors that impact reovirus replication, dissemination, and reovirus-induced cell death in cancer versus normal cells in culture.
Shmulevitz M; Lee PW
Methods Mol Biol; 2012; 797():163-76. PubMed ID: 21948476
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors.
Rodríguez Stewart RM; Berry JTL; Berger AK; Yoon SB; Hirsch AL; Guberman JA; Patel NB; Tharp GK; Bosinger SE; Mainou BA
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511390
[TBL] [Abstract][Full Text] [Related]
8. The effects of oncolytic reovirus in canine lymphoma cell lines.
Hwang CC; Umeki S; Igase M; Coffey M; Noguchi S; Okuda M; Mizuno T
Vet Comp Oncol; 2016 Aug; 14 Suppl 1():61-73. PubMed ID: 25319493
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic viral therapy using reovirus.
Thirukkumaran C; Morris DG
Methods Mol Biol; 2009; 542():607-34. PubMed ID: 19565924
[TBL] [Abstract][Full Text] [Related]
10. Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming.
Steele L; Errington F; Prestwich R; Ilett E; Harrington K; Pandha H; Coffey M; Selby P; Vile R; Melcher A
Mol Cancer; 2011 Feb; 10():20. PubMed ID: 21338484
[TBL] [Abstract][Full Text] [Related]
11. Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling.
McEntee G; Kyula JN; Mansfield D; Smith H; Wilkinson M; Gregory C; Roulstone V; Coffey M; Harrington KJ
Oncotarget; 2016 Jul; 7(30):48517-48532. PubMed ID: 27384486
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic reovirus effectively targets breast cancer stem cells.
Marcato P; Dean CA; Giacomantonio CA; Lee PW
Mol Ther; 2009 Jun; 17(6):972-9. PubMed ID: 19293772
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic Viral Therapy Using Reovirus.
Thirukkumaran C; Morris DG
Methods Mol Biol; 2015; 1317():187-223. PubMed ID: 26072409
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus.
Prestwich RJ; Errington F; Steele LP; Ilett EJ; Morgan RS; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
J Immunol; 2009 Oct; 183(7):4312-21. PubMed ID: 19734207
[TBL] [Abstract][Full Text] [Related]
15. Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.
Jennings VA; Ilett EJ; Scott KJ; West EJ; Vile R; Pandha H; Harrington K; Young A; Hall GD; Coffey M; Selby P; Errington-Mais F; Melcher AA
Int J Cancer; 2014 Mar; 134(5):1091-101. PubMed ID: 23982804
[TBL] [Abstract][Full Text] [Related]
16. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity.
Prestwich RJ; Errington F; Ilett EJ; Morgan RS; Scott KJ; Kottke T; Thompson J; Morrison EE; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
Clin Cancer Res; 2008 Nov; 14(22):7358-66. PubMed ID: 19010851
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.
Gujar SA; Clements D; Dielschneider R; Helson E; Marcato P; Lee PW
Br J Cancer; 2014 Jan; 110(1):83-93. PubMed ID: 24281006
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
Heinemann L; Simpson GR; Boxall A; Kottke T; Relph KL; Vile R; Melcher A; Prestwich R; Harrington KJ; Morgan R; Pandha HS
BMC Cancer; 2011 Jun; 11():221. PubMed ID: 21645351
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release.
Garant KA; Shmulevitz M; Pan L; Daigle RM; Ahn DG; Gujar SA; Lee PW
Oncogene; 2016 Feb; 35(6):771-82. PubMed ID: 25961930
[TBL] [Abstract][Full Text] [Related]
20. The oncolytic effects of reovirus in canine solid tumor cell lines.
Igase M; Hwang CC; Coffey M; Okuda M; Noguchi S; Mizuno T
J Vet Med Sci; 2015 May; 77(5):541-8. PubMed ID: 25648933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
